Hodgkin disease was the first defined lymphoid neoplasm. For many decades it was regarded as a disease separate from non-Hodgkin lymphoma. However, recent studies have shown that the dysplastic cells of Hodgkin lymphoma (HL) are monoclonal B cells. This finding raised again the question "Is HL just another B-cell lymphoma?" This article reviews the different aspects of HL and B-cell non-Hodgkin lymphoma (B-NHL), concluding that-despite the same cell of origin-fundamental differences exist in morphology, cellular composition, immunophenotype, activation or inhibition of transcription factors, epigenetics, and clinical behavior. These findings lead us to conclude that HL and B-NHLs should stay as two separate categories.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11899-009-0018-1 | DOI Listing |
Cureus
November 2024
Family Medicine, UCSP Paço de Arcos, Unidade Local de Saúde Lisboa Ocidental, Lisbon, PRT.
Hodgkin lymphoma (HL) is a monoclonal lymphoid neoplasm derived from B cells and is one of the most common lymphomas among young adults in developed countries. It typically presents insidiously, often as a painless cervical lymphadenopathy or an asymptomatic mediastinal mass. B symptoms (fever, night sweats, and weight loss), fatigue, pruritus, or alcohol-induced pain may be present along with respiratory symptoms in cases of mediastinal involvement.
View Article and Find Full Text PDFNeoplasia
December 2024
Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, PR China. Electronic address:
Primary central nervous system diffused large B-cell lymphoma (PCNS-DLBCL) is a rare type of non-Hodgkin lymphoma restricted to the central nervous system (CNS). To explore its specific pathogenesis and therapeutic targets, we performed multi-omics sequencing on tumor samples from patients diagnosed with PCNS-DLBCL, secondary CNS-DLBCL or extracranial (ec) DLBCL.By single-cell RNA sequencing, highly proliferated and dark zone (DZ)-related B cell subclusters, MKI67_B1, PTTG1_B2 and BTG1_B3, were predominant significantly in PCNS-DLBCL.
View Article and Find Full Text PDFHematol Oncol
January 2025
Département d'Hématologie, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Brentuximab vedotin (BV)-bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single-center analysis of 44 patients with R/R HL treated with one-day BV-bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo).
View Article and Find Full Text PDFLeuk Lymphoma
December 2024
Department of Internal Medicine, Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA.
J Pers Med
December 2024
Radiological Sciences Section, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, AOUP "Paolo Giaccone", Via del Vespro 129, 90127 Palermo, Italy.
Nasal and paranasal sinus masses can arise from a wide range of conditions, both benign and malignant, as well as congenital or acquired. Diagnosing these masses is often challenging, requiring a combination of nasal endoscopy, imaging studies, and histopathological analysis. Initial imaging frequently involves computed tomography or cone beam computed tomography (CBCT) to evaluate the bony anatomy of the nasal cavity and surrounding sinuses, while magnetic resonance imaging (MRI) is typically used for detailed assessment of soft tissues and to aid in differential diagnosis when the findings are inconclusive.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!